Costanzo (Sidemast): "Upadacitinib Blocks Inflammatory Cells in Vitiligo and Alopecia Areata"
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.6 Articles
6 Articles
canaledieci.it
(Adnkronos) • • L •upadacitinib is a small molecule that is taken orally and that blocks a specific point of the immune system: the one that allows the transmission of the signal of inflammation within the inflammatory cells. The new treatment has been approved for both indications on the same day • Vitiligo and alopecia aareata •and this is [...]
(Adnkronos) "L"upadacitinib is a small molecule that is taken orally and that blocks a specific point of the immune system: the one that allows the transmission of the signal of inflammation within the inflammatory cells. The new treatment has been approved for both indications on the same day, vitiligo and alopecia aareata "and this is [...] L'articolo Costanzo (Sidemast): "Upadacitinib blocks inflammatory cells in vitiligo and alopecia areaata…
It is a medicine already approved for other indications, which we therefore know very well, and to which these two new pathologies are now added, vitiligo and alopecia aareata, for which there is a very high request from the patients. Before seeing the treatment available also in Italy, usually passes little less than a year, depends on Aifa, the Italian Agency of the drug.
(Adnkronos) - "It is a drug already approved for other indications, which we therefore know very well,...
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
